Genetic Delivery of Bevacizumab to Suppress Vascular Endothelial Growth Factor-Induced High-Permeability Pulmonary Edema
- 1 June 2009
- journal article
- research article
- Published by SAGE Publications in Human Gene Therapy
- Vol. 20 (6) , 598-610
Abstract
High-permeability pulmonary edema causing acute respiratory distress syndrome is associated with high mortality. Using a model of intratracheal adenovirus (Ad)-mediated overexpression of human vascular endothelial growth factor (VEGF)-A165 in mouse lung to induce alveolar permeability and consequent pulmonary edema, we hypothesized that systemic administration of a second adenoviral vector expressing an anti-VEGF antibody (AdαVEGFAb) would protect the lung from pulmonary edema. Pulmonary edema was induced in mice by intratracheal administration of AdVEGFA165. To evaluate anti-VEGF antibody therapy, the mice were treated intravenously with AdαVEGFAb, an adenoviral vector encoding the light and heavy chains of an anti-human VEGF antibody with the bevacizumab (Avastin) antigen-binding site. Lung VEGF-A165 and phosphorylated VEGF receptor (VEGFR)-2 levels, histology, lung wet-to-dry weight ratios, and bronchoalveolar lavage fluid (BALF) levels of total protein were assessed. Administration of AdαVEGFAb to mice decreased AdVEGFA165-induced levels of human VEGF-A165 and phosphorylated VEGFR-2 in the lung. Histological analysis of AdαVEGFAb-treated mice demonstrated a reduction of edema fluid in the lung tissue that correlated with a reduction of lung wet-to-dry ratios and BALF total protein levels. Importantly, administration of AdαVEGFAb 48 hr after induction of pulmonary edema with AdVEGFA165 was effective in suppressing pulmonary edema. Administration of an adenoviral vector encoding an anti-VEGF antibody that is the equivalent of bevacizumab effectively suppresses VEGF-A165-induced high-permeability pulmonary edema, suggesting that anti-VEGF antibody therapy may represent a novel therapy for high-permeability pulmonary edema.Keywords
This publication has 77 references indexed in Scilit:
- Developmental Regulation of NO-Mediated VEGF-Induced Effects in the LungAmerican Journal of Respiratory Cell and Molecular Biology, 2008
- The epithelium in acute lung injury/acute respiratory distress syndromeCurrent Opinion in Critical Care, 2008
- Acute respiratory distress syndromeBMJ, 2007
- Essential role of nitric oxide in VEGF-induced, asthma-like angiogenic, inflammatory, mucus, and physiologic responses in the lungProceedings of the National Academy of Sciences, 2006
- VEGF receptor signalling ? in control of vascular functionNature Reviews Molecular Cell Biology, 2006
- Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapyBiochemical and Biophysical Research Communications, 2005
- Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancerNature Reviews Drug Discovery, 2004
- The biology of VEGF and its receptorsNature Medicine, 2003
- Antibody Humanization Using Monovalent Phage DisplayJournal of Biological Chemistry, 1997
- Tumor Angiogenesis: Therapeutic ImplicationsNew England Journal of Medicine, 1971